Fig. 1From: Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe diseaseImpact of the different early treatments on the median length time to negativization of SARS-CoV-2 nasal swabBack to article page